Testosterone Deficiency, Weakness, and Multimorbidity in Men

Mark D. Peterson1, Aleksandr Belakovskiy2, Ryan McGrath1 & Joshua F. Yarrow3,4

The purposes of this study were to evaluate the association between total testosterone (TT) deficiency and weakness on multimorbidity in men. Analyses were performed to examine the prevalence of multimorbidity among young, middle-aged, and older men, with and without testosterone deficiency. Multivariate logistic models were also used to determine the association between age-specific TT tertiles and multimorbidity, adjusting for key sociodemographic variables, as well as a secondary analysis adjusted for grip strength. Multimorbidity was more prevalent among men with testosterone deficiency, compared to normal TT in the entire group (36.6% vs 55.2%; \( p < 0.001 \)); however, differences were only seen within young (testosterone deficiency: 36.4%; normal TT: 13.5%; \( p < 0.001 \)) and older men (testosterone deficiency: 75.0%; normal TT: 61.5%; \( p < 0.001 \)). Robust associations were found between the age-specific low-TT (OR: 2.87; 95%CI: 2.14–3.83) and moderate-TT (OR: 1.67; 95%CI: 1.27–2.20) tertiles (reference high-TT) and multimorbidity. Secondary analysis demonstrated that both low TT (OR: 1.82; 95%CI: 1.29–2.55) and moderate-TT (OR: 1.31; 95%CI: 1.01–1.69) were associated with multimorbidity, even after adjusting for obesity (OR: 1.75; 95%CI: 1.07–2.87) and NGS (OR: 1.21 per 0.05 unit lower NGS). Low TT and weakness in men were independently associated with multimorbidity at all ages; however, multimorbidity was more prevalent among young and older men with testosterone deficiency.

The prevalence of total testosterone (TT) deficiency in men increases with age1–3, and is associated with several deleterious effects to the musculoskeletal system including osteopenia and sarcopenia3, as well as with higher rates of all-cause mortality4–9. Recent studies have also suggested that testosterone deficiency is independently and robustly associated with various obesity-related chronic diseases in men, including type 2 diabetes and cardiovascular disease9–11. However, there is uncertainty as to what constitutes optimal physiological levels of TT among men across different age categories, and to the effects that varying TT levels have on disease risk12. This debate is partially fueled by inconsistent findings in the literature and differences across expert clinical recommendations, as well as an incomplete understanding of the underlying mechanisms and temporal sequence of events leading to and stemming from testosterone deficiency. For example, the authors of a well-known systematic review assert that although testosterone deficiency is robustly associated with obesity, insulin resistance, low high-density lipoprotein (HDL) cholesterol and elevated triglycerides, low-density lipoprotein (LDL) cholesterol, and plasminogen activator type 1, there is insufficient evidence to demonstrate a causal role of endogenous testosterone deficiency on coronary artery disease13—the leading cause of preventable death among men in the U.S.14.

Harmonized reference ranges for TT were recently established by combining cohort studies in the U.S. and Europe15. That investigation effectively defined “normal ranges” for TT levels in young healthy men, which may help limit misdiagnosis of testosterone deficiency. However, those ranges were derived from non-nationally representative pooled data across cohorts that do not reflect the growing, ethnically-diverse U.S. population, and in which individuals with several morbid conditions were excluded. Therefore, the primary purpose of this study was to evaluate the association between TT deficiency and prevalent chronic multimorbidity in a large, population-representative sample of U.S. men. We also sought to determine a dose-response trend by examining the effect of age-specific TT tertiles on multimorbidity.

1Department of Physical Medicine & Rehabilitation, Michigan Medicine, University of Michigan, Ann Arbor, USA.
2Department of Family Medicine, Michigan Medicine, University of Michigan Research Service, Ann Arbor, USA.
3Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, USA. 4Division of Endocrinology, Diabetes, and Metabolism, University of Florida College of Medicine, Gainesville, USA. Correspondence and requests for materials should be addressed to M.D.P. (email: mdpeterz@med.umich.edu)
Research Design and Methods

Study Population. The National Health and Nutrition Examination Survey (NHANES) is a program of studies designed to assess the health and nutritional status of adults and children in the United States. The 2011–2012 NHANES survey was chosen based on the wealth of race/ethnicity specific information pertaining to chronic diseases, total testosterone, and direct measures of muscle strength capacity. The analyses were performed in 2016–2017. This survey is unique in that it combines interviews and physical examinations; however, not all participants in the physical exam are included. Of the 2,399 men in the 2011–2012 NHANES survey who were at least 20 years old, 2,161 had complete data for (1) demographic and anthropometric information; (2) valid questionnaire data pertaining to chronic disease diagnoses (e.g., diabetes); (3) the necessary blood samples obtained for serum TT determination; (4) valid strength data from a handgrip dynamometer; and (5) the necessary examination or laboratory assessments for cardiometabolic disease risk factors. Ethical approval was obtained through the National Center for Health Statistics (NCHS) Research Ethics Review Board (Protocol #2011-17). All procedures followed were in accordance with the ethical standards of the NCHS Research Ethics Review Board, and with the Helsinki Declaration, and informed consent was obtained from all patients included in the study.

Demographic and Anthropometric Factors. Socio-demographic characteristics were self-reported during the in-home interview. Age was used as a categorical variable as (1) 20–39.9 years, (2) 40–59.9 years, and (3) ≥60 years old. Race/ethnicity was categorized as: (1) non-Hispanic white, (2) non-Hispanic black, (3) Mexican American or other Hispanic, and (4) Other-including multi-racial. Education was categorized as: (1) less than high school graduate, (2) high school graduate/general educational development (GED) or equivalent, and/or some college or Associate's degree, and (3) college graduate or above. Marital status was dichotomized as married or not married. Annual household income was categorized as: (1) ≤$24,999, (2) $25,000-$54,999, (3) $55,000-$74,999, and (4) ≥$75,000.

Weight was measured using a digital Toledo scale (Metller-Toledo International, Inc., Columbus, OH), and participants only wore an underwear gown and foam slippers. Height was measured using a fixed stadiometer. BMI was calculated as weight in kilograms divided by height in meters squared (kg/m²). Standard categories were applied to determine if each participant was obese (≥30 kg/m²). Individuals with BMI <18.5 kg/m² were excluded, due to the known association between underweight status and chronic disease risk. Waist circumference was measured to the nearest 0.1 cm at the level of the iliac crest. Standard cut points for abdominal obesity in men (>102 cm) were used.

Self-Reported Health Conditions. The NHANES collects self-reported primary health conditions by asking whether the participant has “ever been told by a doctor or health professional” that he or she has a health condition. For this study, the prevalence of 7 self-reported chronic conditions was evaluated, including diagnosis of: type 2 diabetes, arthritis, cardiovascular disease (congestive heart failure, coronary heart disease, and/or angina), stroke, pulmonary disease (emphysema), hypertension, and clinical depression. Clinical depression was dichotomized as a score of ≥10 on the 9-item Patient Health Questionnaire. Scores of 10 or higher have high sensitivity and specificity for identifying major depression in a primary care setting.

Examination and Laboratory Cardiometabolic Abnormalities. In addition to the aforementioned self-reported health conditions, participants were tested on routine cardiometabolic parameters with physical examination and laboratory assessments. Detailed descriptions of the laboratory protocols are provided in the NHANES Laboratory Procedures Manual (https://www.cdc.gov/nchs/data/nhanes/2011-2012/manuals/2011-12_Laboratory_Procedures_Manual.pdf). Resting systolic and diastolic blood pressures were measured three to four times with a mercury sphygmomanometer by trained staff. Fasting and non-fasting measures of HDL-cholesterol, triglycerides, and glucose were measured. Non-fasting serum measures of glycated hemoglobin (HbA1c) were included as a diagnostic test for untreated diabetes, which reflects average plasma glucose for the previous ~three-months.

The diagnostic criterion for diabetes was defined as self-reported diabetes, elevated fasting glucose (≥126 mg/dL), or HbA1c values ≥6.5% (≥48 mmol/mol)44. Participants with diabetes that were being treated with only insulin alone were excluded, as they were considered likely to have type 1 diabetes. Hypertension was defined as self-reported history of hypertension (i.e., physician diagnosis on 2 or more different visits), a systolic blood pressure ≥140 mmHg, or a diastolic blood pressure ≥90 mmHg. Hypertriglyceridemia was determined as ≥150 mg/dL, and low HDL-cholesterol was determined as <40 mg/dL and <50 mg/dL for men and women, respectively.

Multimorbidity. Multimorbidity was defined as the presence of at least two chronic conditions among a list of the nine aforementioned self-reported chronic diseases or examination/laboratory cardiometabolic abnormalities (i.e., diabetes, hypertension, arthritis, cardiovascular disease, stroke, emphysema, hypertriglyceridemia, low-HDL cholesterol, and clinical depression). These conditions were selected in accordance with guidance from the literature pertaining to older adults and adults with disabilities, and availability and reliability of the diagnosis within our clinical data.

Exposure Variable. TT levels were measured in serum using isotope dilution liquid chromatography tandem mass spectrometry by the National Center for Environmental Health, Centers for Disease Control and Prevention. This method employed LLE extractions of serum to isolate the steroid. Stable Isotope-labeled testosterone is used as an internal standard to correct for sample recovery during the sample preparation process. The assay imprecision is 5% and the method is traceable to an established higher-order testosterone reference method (see: https://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/tst_g_met.pdf). Testosterone deficiency was categorized as <300 ng/dL (10.4 nmol/L)25. Age-category-specific TT tertiles were created for use in the logistic regression analyses, as the: (1) highest TT tertile (ages 20–39.9 years: >488 ng/dL; ages 40–59.9 years: >440 ng/dL;
and ≥60 years: 433–440 ng/dL; (2) medium TT tertile (ages 20–39.9 years: 347–488 ng/dL; ages 40–59.9 years: 291–440 ng/dL; and ≥60 years: 290–433 ng/dL); and lowest TT tertiles (ages 20–39.9 years: <347 ng/dL; ages 40–59.9 years: <291 ng/dL; and ≥60 years: <290 ng/dL).

**Covariate.** Muscle strength was assessed using a hydraulic handgrip dynamometer (Takei Digital Grip Strength Dynamometer, Model T.K.K.5401). Detailed descriptions of the protocol are provided in the NHANES Muscle Strength/Grip Test Procedure Manual. A trained examiner explained and demonstrated the protocol to each participant, then adjusted the grip size of the dynamometer to the participant’s hand size, and asked the participant to squeeze the dynamometer for a practice trial. Participants were randomly assigned to start the test with the dominant or non-dominant hand, and asked to squeeze the dynamometer with maximal effort, exhaling while squeezing. Each hand was tested three times. Grip strength was normalized (NGS) as strength per body mass.

**Statistical analysis.** All statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). NHANES employs a multistage sampling design. Sample weights were used to adjust for oversampling, survey nonresponse, and post-stratification. Further, we took into account subsample weights since we conducted analyses on persons with non-fasting glucose measure. These weights were used to produce unbiased estimates. To obtain correct variance estimation, information on strata and primary sampling unit (PSU) were also utilized. Differences in these characteristics across age categories and for testosterone deficiency were tested using linear regression (proc surveyreg) and logistic regression (proc surveymlogistic) for continuous and categorical variables respectively, after creating appropriate categories and dummy coding for each. Partial correlation statistics were conducted to examine the association between TT and NGS, while adjusting for age, race/ethnicity, education and household income.

To assess the odds of multimorbidity in the entire sample, we utilized the univariate and multivariate logistic regression modeling approaches. For model 1, only age-category-specific TT tertiles were entered as the primary exposure variable (reference: High TT tertile). For model 2, further adjustments for known demographic covariates, including age categories, race, education, annual income, and marital status, were included in each model. Lastly, in order to examine whether the association between TT and multimorbidity was explained in whole or part by obesity or NGS capacity, a third model was performed including (1) age-category-specific TT tertiles; (2) all sociodemographic variables; (3) obesity status; and (4) NGS (with units set to 0.05).

**Data availability.** All data are publically available and were obtained through the CDC’s National Health and Nutrition Examination Survey website: https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear = 2011.

**Results**

The descriptive data of all 2,399 men are presented across age categories in Table 1. Obesity, waist circumference, and most cardiometabolic health parameters were significantly lower among young men (p < 0.001); however, in many cases, middle-aged men had worse cardiometabolic profiles than young and older men. Absolute grip strength and NGS were both significantly lower across higher age categories (p < 0.001). Moreover, TT was highest among young men (p < 0.001); however, there were no differences in TT between middle-aged and older men.

**Chronic Disease Risk Factors and Multimorbidity.** For the full sample, the mean number of chronic disease risk factors was 1.5 ± 1.3, with hypertension as the most prevalent individual condition (48.6%), followed by hypertriglyceridemia (28%), low HDL-C (26.8%), arthritis (19.7%), diabetes (17.9%), clinical depression (7.4%), CVD (7.2%), stroke (4%), and pulmonary disease (2.5%).

The prevalence of multimorbidity was 41.3% for all men; however, there was a significant age association (p < 0.001). For young, middle-aged, and older men, the prevalence of multimorbidity was 17.4%, 44.2%, and 65.3%, respectively. Of the 502 total possible combinations of multimorbidity, we found 58 unique multimorbidity combinations, and the most prevalent combinations were: (a) hypertension and arthritis (n = 107); (b) hypertension and low HDL-C (n = 103); (c) diabetes and hypertension (n = 86); (d) hypertension and hypertriglyceridemia (n = 50); hypertriglyceridemia and low HDL-C (n = 47); and diabetes, hypertension, and arthritis (n = 42).

**Testosterone Deficiency.** Prevalence of testosterone deficiency (<300 ng/dL [10.4 nmol/L]) was 30.8% for the entire sample, and 22.6%, 35.8%, and 34.6% for young, middle-aged, and older men, respectively. Significant higher prevalences of individual chronic diseases were found between men with testosterone deficiency as compared to men with normal TT (Table 2). Further, multimorbidity was significantly more prevalent among men with testosterone deficiency, compared to normal TT in the entire group (36.6% vs 35.2%; p < 0.001); however, differences were only seen within the younger (testosterone deficiency: 36.4%; normal TT: 13.5%; p < 0.001) and older men (testosterone deficiency: 75.0%; normal TT: 61.5%; p < 0.001) (Fig. 1).

Both TT and NGS were robustly associated with multimorbidity (p < 0.001). Secondary analysis demonstrated that TT was significantly correlated to NGS (r = 0.35; p < 0.001) (Fig. 2), even after adjusting for age, race/ethnicity, income and education. Unadjusted and adjusted logistic models revealed a robust association between the age-specific low-TT and moderate-TT tertiles (reference high TT tertiles) and multimorbidity (Table 3). In the final multiple logistic model, both low TT and moderate-TT tertiles were still significantly associated with multimorbidity even after adjusting for NGS (Table 4)
Significant difference between ages 20–39.9 years and 40–59.9 years

Testosterone deficiency, within the same category.

HOMA-Homeostasis Model of Assessment; HDL-high density lipoprotein; LDL-low density lipoprotein. aGrip strength in kg divided by body mass in kg.

Table 1. Descriptive and health characteristics of the young (20–39.9 years), middle-aged (40–59.9 years) and older (≥60 years) men; Mean (standard deviation) or percentages. Abbreviations: BMI-body mass index; WC-waist circumference; NGS-Normalized Grip Strength; TT-Total Testosterone; HbA1c-Glycated Hemoglobin; WC-Abdominal Obesity (WC ≥102 cm), % 29.3 43.7‡ 50.23

Table 2. Prevalence (%) of chronic conditions/diseases between men with testosterone deficiency (<300 ng/dL [10.4 nmol/L]) versus those with normal TT. *Significant difference between subjects with and without Testosterone deficiency, within the same category.

Discussion

The principal findings of this study were that TT deficiency was robustly and independently associated with multimorbidity in a large population-representative sample of U.S. men. Moreover, there was strong evidence supporting a dose-response trend for TT and multimorbidity risk. Specifically, the lowest age-category-specific TT tertile and the middle age-category-specific TT tertile were associated a 3-fold and nearly 75% higher multimorbidity risk, when compared to the highest age-category-specific tertiles of TT. Our results support the findings of several other large population-based prospective studies that indicate increased all-cause mortality and cardiovascular risks in both young and older men within the lowest ranges of TT, in comparison to men in the highest5–7,24. The dose-response trend we observed remained significant even after adjusting for grip strength, a known, robust predictor of chronic disease and early mortality in men5,26. Similarly, others have reported
reduced all-cause and cardiovascular mortality accompany each 1 standard deviation, or 1 nmol/L, incremental increase in TT, even for men in the eugonadal range.11,24,27. Further, a large meta-analysis of observational studies (n = 16,184 men) reported a 55% higher all-cause mortality (RR: 1.55; 95% CI: 1.28 to 1.88) for studies with baseline TT \( \leq \) 487 nd/dl7, suggesting a threshold for increased mortality that is very near our TT cutoffs for the highest age-category-specific tertiles.

We have also uncovered interesting age disparities in testosterone deficiency and multimorbidity prevalence in our population-representative sample of U.S. men. Specifically, there was a much lower median TT in the youngest age category of men from our study (419 ng/dL), as compared to previous clinical cohort studies which harmonized TT reference ranges from healthy, non-obese men of the same age (533 and 529 ng/dL)15. This is very likely due to (1) the previous cohort populations, which were mainly men identified as white; (2) exclusion of ~5% of men who exhibited pituitary, testicular or adrenal disease, or who used medications that affect sex-steroid production from the European Male Aging Study, and those with BMI > 30 kg/m² from the Belgium Siblings Study of Osteoporosis15; and (3) the lack of adjustment for important sociodemographic factors such as race/ethnicity, income, education, and marital status. Moreover, the recently published harmonized 2.5th, 5th, 50th, 95th, and 97.5th percentiles were 264, 303, 531, 852, and 916 ng/dL, respectively, for healthy, non-obese men aged 19–39 years. Currently used cutoffs to diagnose TT deficiency (\(<300\) ng/dL \([10.4\ \text{nmol/L}]\)) would therefore correspond with the 5th percentile of the reference range; however, in our study the 5th percentile among young men aged 20–39 corresponded with a TT of 182 ng/dL.

Moreover, multimorbidity was significantly more prevalent among men with testosterone deficiency, compared to normal TT in the entire group (36.6% vs 55.2%); and yet, these differences seem to have been largely driven by differences in multimorbidity for young and older men. Despite strong evidence of worse chronic disease risk profiles among middle aged men with testosterone deficiency, as compared to middle-aged men with normal TT, the differences in multimorbidity were not statistically different. Collectively, this demonstrates the importance of screening TT among young men, particularly those with existing obesity, diabetes, cardiovascular

---

**Figure 1.** Multimorbidity prevalence between men with low TT versus normal TT, across age categories.

---

**Figure 2.** Partial residual scatter plot revealing the correlations between total testosterone and normalized strength capacity after adjustment for age, race/ethnicity, education, and income.
disease, hypertension, clinical depression, low HDL cholesterol, or hypertriglyceridemia, as each of these conditions were significantly higher in those with testosterone deficiency. This is in accordance with the 2016 American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity.

| Model Predictor(s)                              | Odds Ratio | 95% CI       | Pr > ChiSq |
|------------------------------------------------|------------|--------------|------------|
| Unadjusted Model                               |            |              |            |
| Total Testosterone Tertiles (Ref: High Testosterone) |            |              |            |
| Low Testosterone                               | 2.18       | 1.71–2.79    | <0.001     |
| Medium Testosterone                            | 1.39       | 1.09–1.77    | 0.01       |
| Model 2: Sociodemographic Adjusted             |            |              |            |
| Age Category (Ref: 20–39 years)                |            |              |            |
| Age 40–59.9 years                              | 4.52       | 3.19–6.42    | <0.001     |
| Age ≥ 60 years                                 | 9.19       | 6.87–12.31   | <0.001     |
| Race/ethnicity (Ref: Non-Hispanic White)       |            |              |            |
| Non-Hispanic black                             | 0.98       | 0.76–1.26    | 0.86       |
| Hispanic or Mexican American                   | 1.04       | 0.79–1.37    | 0.79       |
| Other, including multi-racial                  | 0.96       | 0.61–1.49    | 0.85       |
| Education Level (Reference: College Graduate)  |            |              |            |
| <High School Graduate                          | 1.67       | 0.89–3.14    | 0.11       |
| Some College                                   | 1.43       | 0.79–2.61    | 0.24       |
| Marital Status (Reference: Unmarried)          | 1.09       | 0.76–1.56    | 0.66       |
| Income Level (Reference: ≥$75,000)             |            |              |            |
| <$25,000                                       | 2.11       | 1.37–3.25    | 0.01       |
| $25,000–$54,999                                | 1.22       | 0.79–1.90    | 0.37       |
| $55,999–$74,999                                | 1.32       | 0.89–1.95    | 0.16       |
| Total Testosterone Tertiles (Ref: High Testosterone) |            |              |            |
| Low Testosterone                               | 2.87       | 2.14–3.83    | <0.001     |
| Medium Testosterone                            | 1.67       | 1.27–2.20    | <0.001     |

Table 3. Univariate and sociodemographic-adjusted logistic regression models for multimorbidity in adult men. *Denotes age-category specific Total Testosterone Tertiles.

| Model Predictor(s)                              | Odds Ratio | 95% CI       | Pr > ChiSq |
|------------------------------------------------|------------|--------------|------------|
| Age Category (Ref: 20–399 years)                |            |              |            |
| Age 40–59.9 years                               | 3.62       | 2.43–5.40    | <0.001     |
| Age ≥ 60 years                                  | 6.23       | 4.07–9.54    | <0.001     |
| Obesity (BMI ≥30)                               | 1.75       | 1.07–2.87    | 0.03       |
| Race/ethnicity (Ref: Non-Hispanic White)        |            |              |            |
| Non-Hispanic black                             | 1.08       | 0.79–1.46    | 0.63       |
| Hispanic or Mexican American                    | 0.97       | 0.71–1.33    | 0.85       |
| Other, including multi-racial                   | 1.13       | 0.75–1.68    | 0.57       |
| Education Level (Reference: College Graduate)   |            |              |            |
| <High School Graduate                          | 1.52       | 0.76–3.02    | 0.23       |
| Some College                                   | 1.27       | 0.70–2.30    | 0.43       |
| Marital Status (Reference: Unmarried)           | 1.29       | 0.82–2.03    | 0.27       |
| Income Level (Reference: ≥$75,000)              |            |              |            |
| <$25,000                                       | 2.41       | 1.53–3.80    | <0.001     |
| $25,000–$54,999                                | 1.24       | 0.79–1.94    | 0.36       |
| $55,999–$74,999                                | 1.21       | 0.77–1.89    | 0.41       |
| Total Testosterone Tertiles (Ref: High Testosterone) |            |              |            |
| Low Testosterone                               | 1.82       | 1.29–2.55    | <0.001     |
| Medium Testosterone                            | 1.31       | 1.01–1.69    | 0.04       |
| Normalized Grip Strength                        | 1.21       | 1.08–1.35    | <0.001     |

Table 4. Multiple logistic regression models for independent predictors of multimorbidity including the effect of obesity and NGS. *Denotes age-category specific Total Testosterone Tertiles. *OR and 95%CL per each 0.05 unit lower.

The presence of testosterone deficiency was also associated with higher odds of multimorbidity, with the odds ratio (OR) for low testosterone tertiles being 2.18 (95% confidence interval [CI] 1.71–2.79, p < 0.001) compared to the reference group of high testosterone tertiles. The OR for medium testosterone tertiles was 1.39 (95% CI 1.09–1.77, p = 0.01). These findings are consistent with previous studies that have established a link between low testosterone levels and a higher risk of multimorbidity.

In addition to testosterone deficiency, other sociodemographic factors were also associated with multimorbidity. For example, older age (age 40–59.9 years OR 4.52, 95% CI 3.19–6.42, p < 0.001; age ≥ 60 years OR 9.19, 95% CI 6.87–12.31, p < 0.001) and obesity (BMI ≥ 30) OR 1.75, 95% CI 1.07–2.87, p = 0.03) were significant predictors of multimorbidity. Moreover, lower income levels (≤$25,000 OR 2.11, 95% CI 1.37–3.25, p = 0.01) were also associated with a higher risk of multimorbidity.

These results highlight the importance of addressing testosterone deficiency and other sociodemographic factors in the prevention and management of multimorbidity in adult men. Further research is needed to better understand the underlying mechanisms and to develop effective interventions to improve health outcomes in this population.
In patients with multimorbidity, early detection can guide treatment as well as slow progression, or potentially halt disease processes entirely. In this study, among young men there was a strong association between low testosterone and multimorbidity. It is unlikely that end-stage disease was responsible for this finding, and thus it can be hypothesized that low testosterone may play an early, causal role in chronic disease processes. This warrants further research as it could change screening guidelines for testosterone deficiency, as well as have a significant impact on the rates of disease processes such as hypertension and diabetes in men.

Not surprisingly, nearly all research related to the influence of testosterone deficiency to potentiate risk for secondary muscle and metabolic dysfunction in men has been conducted within an aging-related context. However, the underlying changes in hormonal and metabolic dysregulation leading to multimorbidity should be regarded as a gradual continuous process throughout the lifespan, rather than a discrete outcome or event. Thus, further evaluation of the temporal sequence of these consequences is of particular importance not only for screening efforts to reduce chronic disease, but also for informing early, targeted interventions to treat declining TT or testosterone deficiency in men. In this regard, debate surrounding the cardiovascular safety of testosterone replacement therapy (TRT) persists because the Testosterone in Older Men with Mobility Limitations (TOM) trial was discontinued due to a higher prevalence of cardiovascular-related events in the TRT vs placebo groups (even though the study has received criticism primarily due to relatively poor classification of cardiovascular events), and the findings of two large retrospective studies indicated increased cardiovascular disease risk in men receiving TRT (HR: 0.64; 95% CI: 0.43 to 0.96) and MI risk (HR: 0.76; 95% CI: 0.63 to 0.93), in comparison to untreated hypogonadal all-cause mortality (Hazard Ratio [HR]: 0.44; 95% CI: 0.42–0.46) and 24–36% lower stroke risk (though the study has received criticism primarily due to relatively poor classification of cardiovascular events), and the findings of two large retrospective studies indicated increased cardiovascular disease risk in men receiving TRT (HR: 0.64; 95% CI: 0.43 to 0.96) and MI risk (HR: 0.76; 95% CI: 0.63 to 0.93), in comparison to untreated hypogonadal men. Moreover, they remain at odds with data from several recent meta-analyses that indicate TRT does not increase cardiovascular events in hypogonadal men, and with findings of a very large retrospective study (n = 83,010 men with documented low T) that indicated TRT was associated with a 56% lower propensity matched all-cause mortality (Hazard Ratio [HR]: 0.44; 95% CI: 0.42–0.46) and 24–36% lower stroke risk (HR: 0.64; 95% CI: 0.43 to 0.96) and MI risk (HR: 0.76; 95% CI: 0.63 to 0.93), in comparison to untreated hypogonadal men. It is also important to note that the recently published NIH-funded T-trials found no differences in cardiovascular-related or other adverse events among men receiving TRT vs placebo, and there is also recent evidence that TRT is associated with lower mortality rates among diabetic men.

Interestingly, despite that TT and muscle strength are known to be highly associated in men, and that weakness is a known predictor of chronic disease and early mortality, our findings reveal an independent effect of muscle weakness and lower TT on risk for multimorbidity. Future research is needed to better understand the independent and joint effects of low TT and muscular weakness in young adulthood as a risk exposure for multimorbidity tracking into/throughout middle-age and older adulthood.

**Limitations.** The design of this study was limited by the cross-sectional design of NHANES, which posed challenges in causal inference, especially with respect to reverse causation. Thus, we are unable to deduce whether low TT leads to higher odds of multimorbidity, or conversely, whether poor chronic health profiles lead to declines in TT levels. Moreover, we were unable to determine if other competing risks or unmeasured confounding (e.g., dietary habits, medication use) may have influenced the observed estimates. Future longitudinal studies are needed to better understand how declines in TT contribute to unhealthy aging, as well as the extent to which other chronic conditions (e.g., obesity, diabetes) may mediate the association between low TT, and multimorbidity and mortality. Third, we did not have access to sex hormone-binding globulin or free testosterone for these men, and thus we could not determine the differential contribution of these compared to TT for prediction of multimorbidity across the age spectrum. Lastly, we found no statistical differences in TT and testosterone deficiency between middle aged and older men, a finding that might be due to an underrepresentation of institutionalized older men.

**Conclusions**

Our results suggest a much higher prevalence of testosterone deficiency occurs in men across the adult age-span than what has been previously reported, and that young and elderly men with testosterone deficiency exhibit a significantly higher multimorbidity risk than their eugonadal counterparts.

**References**

1. Harman, S. M. et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. *J. Clin. Endocrinol. Metab.* **86**, 724–731, 86.2. 7219 (2001).
2. Deutschbein, T., Mann, K. & Petersen, S. Total Testosterone and Calculated Estimates for Free and Bioavailable Testosterone: Influence of Age and Body Mass Index and Establishment of Sex-Specific Reference Ranges. *Horm. Metab. Res.* **47**, 846–854 (2015).
3. Bost, S. E. & Yarrow, J. F. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men. *Am J Physiol. Endo.Metab.* **308** (2015).
4. Muraldeharian, V., Marsh, H., Kapoor, D., Channer, K. S. & Jones, T. H. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. *Eur J Endocrinol.* **169**, 725–733 (2013).
5. Tivesten, A. et al. Low serum testosterone and estradiol predict mortality in elderly men. *J. Clin. Endocrinol. Metab.* **94**, 2482–2488 (2009).
6. Laughlin, G. A., Barrett-Connor, E. & Bergstrom, J. Low serum testosterone and mortality in older men. *J. Clin. Endocrinol. Metab.* **93**, 68–75, https://doi.org/10.1210/jc.2007-1792 (2008).
7. Araujo, A. B. et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. *J. Clin. Endocrinol. Metab.* **96**, 3007–3019 (2011).
8. Hackett, G. et al. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. *Int. J Clin Pract.** **70**, 244–253 (2016).
9. Colangelo, L. A. et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: multi-ethnic study of atherosclerosis. *Diabetes Care.* **32**, 1049–1051 (2009).
10. Corona, G. et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. *Int J Androl.* 34, 528–540, https://doi.org/10.1111/j.1365-2605.2010.01177.x (2011).

11. Ruige, J. B., Mahmoud, A. M., De Bacquer, D. & Kaufman, J. M. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. *Heart.* 97, 870–875 (2011).

12. Aversa, A. & Morgentaler, A. The practical management of testosterone deficiency in men. *Nat Rev Urol.* 12, 641–650 (2015).

13. Wu, F. C. von Eckardstein, A. Androgens and coronary artery disease. *Endocr. Rev.* 24, 183–217 (2003).

14. Heron, M. Deaths: Leading causes for 2014. (National Center for Health Statistics, Hyattsville, MD, 2016).

15. Travison, T. et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the USA and Europe. *J. Clin. Endocrinol. Metab.* 102, 1161–1173 (2017).

16. Sairenchi, T. et al. Underweight as a predictor of diabetes in older adults: a large cohort study. *Diabetes care.* 31, 583–584 (2008).

17. Kroenke, K., Spitzer, R. L. & Williams, J. B. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med.* 16, 606–613 (2001).

18. International Expert, C. et al. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes care.* 32, 1327–1334 (2009).

19. Quinones, A. R., Markwardt, S. & Botoseneanu, A. Multimorbidity Combinations and Disability in Older Adults. *J Gerontol a-Biol.* 71, 823–830 (2016).

20. Salve, M. E. Multimorbidity in Older Adults. *Epidemiologic reviews.* 35, 75–83 (2013).

21. Espeland, M. et al. Clinical Trials Targeting Aging and Age-Related Multimorbidity. *J Gerontol, Series A.* 72, 355–361 (2016).

22. Bhasin, S. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J. Clin. Endocrinol. Metab.* 95, 2536–2559 (2010).

23. NHANES. Muscle Strength Procedures Manual. http://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/Muscle_Strength_Proc_Manual.pdf (2011).

24. Khaw, K. T. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. *Circulation.* 116, 2694–2701 (2007).

25. Peterson, M. D., Zhang, P., Choksi, P., Markides, K. S. & Al Snih, S. Muscle Weakness Thresholds for Prediction of Diabetes in Adults. *Sports Med.* 46, 619–628 (2016).

26. Leong, D. P. et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. *Lancet.* 386, 266–273 (2015).

27. Corona, G. et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. *Eur J Endocrinol.* 165, 687–701 (2011).

28. Carver, W. T. et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. *Endocr Pract.* 22(Suppl 3), 1–203 (2016).

29. Basaria, S. et al. Adverse Events Associated with Testosterone Administration. *New Engl J Med.* 363, 109–122 (2010).

30. Morgentaler, A. Words of wisdom. Re: Adverse events associated with testosterone administration. *European urology.* 59, 465 (2011).

31. Vigen, R. et al. Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. *JAMA.* 310, 1829–1836 (2013).

32. Finkle, W. D. et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. *Plos one.* 9, e85805 (2014).

33. Traish, A. M., Guay, A. T. & Morgentaler, A. Death by testosterone? We think not! *The journal of sexual medicine.* 11, 624–629 (2014).

34. Morgentaler, A. & Lunenfeld, B. Testosterone and cardiovascular risk: world’s experts take unprecedented action to correct misinformation. *Aging Male.* 17, 63–65 (2014).

35. Borst, S. E. et al. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. *BMC medicine.* 12, 211 (2014).

36. Onasanya, O., Iyer, G., Lucas, E., Singh, S. & Alexander, G. C. Association Between Exogenous Testosterone and Cardiovascular Events: An Overview of Systematic Reviews. *Lancet Diabetes Endocrinol.* 4, 943–956 (2016).

37. Corona, G. et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. *Expert Opin Drug Saf.* 13, 1327–1351 (2014).

38. Sharma, R. et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. *Eur Heart J.* 36, 2706–2715 (2015).

39. Snyder, P. J. et al. Effects of Testosterone Treatment in Older Men. *JNew Engl J Med.* 374, 611–624 (2016).

40. Hackett, G., Jones, P. W., Strange, R. C. & Ramachandran, S. Statins and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. *World J Diabetes.* 8, 104–111 (2017).

41. Hsu, B. et al. Longitudinal relationships of circulating reproductive hormone with functional disability, muscle mass, and strength in community-dwelling older men: the Concord Health and Ageing in Men project. *J. Clin. Endocrinol. Metab.* 99, 3310–3318 (2014).

Acknowledgements

This work was supported, in-part, by resources provided by the North Florida/South Georgia Veterans Health System. The work reported herein does not represent the views of the US Department of Veterans Affairs or the US Government. Joshua Yarrow is supported, in-part, by resources provided by the North Florida/South Georgia Veterans Health System. The work reported herein does not represent the views of the US Department of Veterans Affairs or the US Government.

Author Contributions

M.P., A.B., and J.Y. conceived the study, M.P. accessed the data and carried out all analyses, M.P., A.B., and R.M. wrote the first draft of the manuscript. J.Y. provided critical input regarding the analysis and content, and helped with writing the final manuscript. All authors provided critical input on and approved the revised manuscript.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
